Mark W. Feinberg
Chief Medical AdvisorDr. Mark W. Feinberg, M.D., serves as Advisor at ORI Capital. He is Chief Medical Advisor of Bluejay Diagnostics, Inc. from January 2022. He is a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH) and an associate professor of medicine at Harvard Medical School (HMS). He is also an affiliated faculty Member at the Harvard Stem Cell Institute. Dr. Feinberg received his medical degree from the Medical College of Pennsylvania. He completed an internal medicine residency at Duke University Medical Center and cardiology fellowships at Harvard School of Public Health and the Brigham and Women’s Hospital. Dr. Feinberg is Board certified in internal medicine and cardiology. Dr. Feinberg’s clinical interests include noninvasive clinical cardiology, vascular medicine, and cardiovascular disease prevention. Dr. Feinberg directs a basic science laboratory that investigates mechanisms leading to the development of atherosclerosis (coronary artery disease) and myocardial infarction (heart attack). These studies have revealed novel and unexpected pathophysiological roles for microRNAs and transcriptional regulators in vascular inflammation and repair, with therapeutic implications for ischemic cardiovascular disease and other acute and chronic inflammatory diseases. Dr. Feinberg has held various leadership roles in cardiovascular research including his service on national peer review study sections, editorial service, and as a Co-Chair of the Brigham Research Institute’s CVDM Center. Dr. Feinberg is Director of Cardiovascular RNA Biology Research at BWH. Dr. Feinberg’s research has resulted in more than 100 peer-reviewed publications, seminars and invited lectures. Dr. Feinberg holds several patents or pending patents for diagnosing, monitoring, or treating inflammation. He has been involved with several clinical trials and has served as an advisor to a number of global pharmaceutical companies. Dr. Feinberg is an honorary Member of the American Society of Clinical Investigation, and his research program has been supported by the American Heart Association and the US National, Heart, Lung, and Blood Institute.
Positions
- Company NameBluejay Diagnostics, Inc.Stock CodeBJDXPositionChief Medical AdvisorColleagues
- IDIndranil DeyPrincipal Financial, Accounting & Executive Officer, President, CEO and Director
- DRDonald R. ChaseIndependent Chairman of the Board
- KVKevin VanceChief Commercial Officer
- MWMark W. FeinbergChief Medical Advisor
- DCDouglas Clark WurthIndependent Director
- FSFrederick Schwartz ZeidmanIndependent Director
- SDSvetlana DeyDirector
